Sunitinib og dets hovedmetabolit er de vigtigste lægemiddelrelaterede forbindelser identificeret i plasma, urin og fæces med henholdsvis 91, 5%, 86, 4% og 73, 8% af radioaktivitet i poolede prøver.
Sunitinib and its primary active metabolite were the major drug-related compounds identified in plasma, urine and faeces, representing 91.5%, 86.4% and 73.8% of radioactivity in pooled samples, respectively.